High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
AssigneeThe Regents of the University of California
InventorsAnna M. Wu, Robert E. Reiter, Eric J. Lepin, James D. Marks, Yu Zhou
Life of this patent
Estimating the term…
Abstract
The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.
Claims33
An antigen binding protein construct that binds to human prostate stem cell antigen (PSCA) comprising an antigen binding domain comprising a heavy chain variable domain comprising the complementarity determining regions (CDRs) of the heavy chain variable domain of SEQ ID NO:
- 7 and a light chain variable domain comprising the CDRs of the light chain variable domain of SEQ ID NO:
- 7.
An antibody that binds to human prostate stem cell antigen (PSCA) comprising an antigen binding domain comprising a heavy chain variable domain comprising the complementarity determining regions (CDRs) of the heavy chain variable domain of SEQ ID NO:
- 7 and a light chain variable domain comprising the CDRs of the light chain variable domain of SEQ ID NO:
- 7.
Dependencies are inferred from the claim text.